Shasun inks pact with SeQuent Scientific to form JV

Tags: Companies
Shasun Pharmaceuticals today inked an deal with SeQuent Scientific to form a joint venture firm to develop and sell veterinary products in global markets.

The company has signed the joint venture agreement with SeQuent to develop, manufacture and sell veterinary products including both API (active pharmaceutical ingredients) and formulations to cater to the global market, Shasun Pharmaceuticals said in a filing to the BSE.

Last year, the companies had inked a Letter of Intent (LOI) to form the joint venture firm.

"In line with the joint venture agreement, company has also executed today a slump sale agreement, transferring its Vizag facility to JV Company," Shasun said.

SeQuent and Shasun will hold 73 per cent and 27 per cent stakes respectively in the JV firm, which is expected to be operational in the first quarter of 2014-15, it added.

Shasun shares were trading at Rs 76.25 apiece on the BSE in the afternoon trade, down 1.49 per cent from its previous close.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • India must take the UN’s lead in recognising gay rights

    In what has by now become a matter of course, our judiciary again demonstrated that it is miles ahead of our government in terms of staying in tune wi

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

Today's Columns

Urs Schoettli

Lee’s legacy will always guide Singapore

LEE Kuan Yew, the father of modern Singapore, died last ...

Rajgopal Nidamboor

Forget the past and embrace the present

It is all right to believe that one should always ...

Bubbles Sabharwal

Relationships and bitter realities

It’s a tangled web we spin The relationships we make, break ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture